Phase I trial of <i>in situ</i> vaccination with autologous <i>CCL21</i>-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC.
Aaron Lisberg(University of California, Los Angeles), Steven M. Dubinett(University of California, Los Angeles), Camelia Dumitras(University of California, Los Angeles), Robert D. Suh(University of California, Los Angeles), Anita Kaul(University of California, Los Angeles), Kanwarpal Kahlon(City Of Hope National Medical Center), Gregory A. Fishbein(University of California, Los Angeles), Raymond J. Lim(University of California, Los Angeles), Jonathan W. Goldman(University of California, Los Angeles), Ramin Salehi‐Rad(University of California, Los Angeles), Linh M. Tran(University of California, Los Angeles), Scott Genshaft(University of California, Los Angeles), Edward B. Garon(University of California, Los Angeles), Kostyantyn Krysan(University of California, Los Angeles), David Elashoff(University of California, Los Angeles), Bin Liu(University of California, Los Angeles), Zhe Jiang(University of California, Los Angeles), Fereidoun Abtin, Shay Ashouri(University of California, Los Angeles), Jay M. Lee(University of California, Los Angeles)
Cited by 2
Related Papers
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2015|664
Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC
|New England Journal of Medicine|2023|605
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|459